Global /Taiwan /Healthcare /Biotechnology /7729

Steminent Biotherapeutics Inc.

7729

• TPEX: 7729 • Delayed

76.50TWD -3.8%

2.42 USD

As of 20 June 2026, Steminent Biotherapeutics Inc. has a market cap of $167.53M USD, ranking #22171 globally and #1059 in Taiwan. It ranks #1993 in the Healthcare sector, and #388 in the Biotechnology industry.

Global Rank

22171

Country Rank

1059

Sector Rank

1993

Industry Rank

388

Key Stats

Market Cap

$167.53MUSD

5.3B TWD

Enterprise Value

$153.97MUSD

4.87B TWD

EBITDA (TTM)

-$4.9MUSD

-155.03M TWD

Net Income (TTM)

-$5.5MUSD

-174.04M TWD

PB Ratio

8.8

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Biotechnology

CEO

Ling-Mei Wang open_in_new

Founded

2009

Website

steminent.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-3.8%	-5.9%	12%	-6.3%	77%	31%	243%	101%	101%

News

Markets

Exchange	Ticker	Price	Quotes
Taipei Exchange (TPEX) MIC: ROCO PRIMARY	7729 仲恩生醫科技股份有限公司 ISIN: TW0007729006 Shares Out.: Shares Outstanding: 73.073M¹ TV: TradingView: TPEX: 7729 SA: Stock Analysis: TPEX: 7729 YF: Yahoo Finance: 7729.TWO GF: Google Finance: TPEX: 7729 BA: Barron's: 7729 MS: Morningstar: ROCO: 7729	76.50 TWD	TV: TradingView: TPEX: 7729 SA: Stock Analysis: TPEX: 7729 YF: Yahoo Finance: 7729.TWO GF: Google Finance: TPEX: 7729 BA: Barron's: 7729 MS: Morningstar: ROCO: 7729

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Steminent Biotherapeutics Inc.

Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It offers Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington’s disease; tissue regeneration, such as osteoarthritis; and acute syndromes comprising acute respiratory distress syndrome, liver failure, and ischemic stoke. The company was founded in 2009 and is based in Taipei, Taiwan.

Similar Companies

Industry: Biotechnology (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
Caliway Biopharmaceuticals Co., Ltd. TWSE: 6919	$5.46B 172.76B TWD 3K%	-	Taiwan
Pell Bio-Med Technology Co., Ltd. TWSE: 6949	$1.61B 50.93B TWD 861%	-	Taiwan
Lin BioScience, Inc. TPEX: 6696	$1.08B 34.04B TWD 543%	-	Taiwan
HanchorBio Inc. TWSE: 7827	$726.25M 22.97B TWD 334%	-	Taiwan
HanchorBio Inc. TPEX: 7827	$600.25M 18.98B TWD 258%	-	Taiwan
Locus Cell Co., Ltd. TPEX: 06891	$571.26M 18.06B TWD 241%	-	Taiwan

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 109K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 95K%	19.0	United States
argenx SE EBR: ARGX	$47.43B 41.39B EUR 28K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.23B 68.19T KRW 26K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.27B 60.27B AUD 25K%	29.3	Australia
Lonza Group AG SIX: LONN	$41.88B 33.71B CHF 25K%	37.2	Switzerland

chevron_leftBack